Lyell Immunopharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lyell Immunopharma Inc 's ROA in the second quarter of 2026?
Lyell Immunopharma Inc recorded a cumulative net loss of $-248 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -70.5%.

However, within the Healthcare sector 663 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4093, from total ROA ranking in the first quarter of 2026 at 4807.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-19.28 %	-18.42 %	-27.15 %	-30.03 %	-37.62 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-248	-246	-274	-326	-331
Return On Assets (TTM)	-70.5 %	-66.41 %	-70.22 %	-77.08 %	-71.07 %
LYEL's Total Ranking	# 4093	# 4807	# 4259	# 4270	# 4277
Total Assets (TTM) in million	311	351	340	408	385
Seq. Total Assets Change	-11.26 %	3.11 %	-16.65 %	5.84 %	-10.32 %
Seq. Net Income Change	-	-	-	-	-

LYEL's 5 Years Annual ROA >> Back to LYEL Management Effectiveness >> Compare LYEL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 304
Sector	# 664
Overall	# 4090

Return On Assets Statistics
High	Average	Low
-3.79 %	-38.03 %	-76 %
(Jun 30 2022)		(Sep 30 2025)

Financial Statements
Lyell Immunopharma Inc 's Assets	$ 311 million	LYEL's Balance sheet
Lyell Immunopharma Inc 's Income	$ -45 million	Quarterly LYEL's Income Statement
LYEL's Income by Division		See LYEL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-23.08 %	-34.47 %	-20.43 %	-17.21 %	-
Total Assets in million	359	467	712	895	1,081
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-274	-343	-235	-183	-250
Annual Return On Assets	-76.44 %	-73.48 %	-32.94 %	-20.45 %	-23.14 %

LYEL's 5 Years Annual ROA >> Back to LYEL Management Effectiveness >> Compare LYEL ROA to its Competitors

More Return On Assets Ratios
LYEL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LYEL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LYEL's Competitors
Subscribers only: Roa for Lyell Immunopharma Inc 's Suppliers
Subscribers only: Return On Assets for LYEL's Customers

You may also want to know
LYEL's Roi	LYEL's Inventory Turnover Ratio	LYEL's Growth Rates	LYEL's Dividend Comparisons
	LYEL's Profitability Ratios	LYEL's Asset Turnover Ratio	LYEL's Dividend Growth
LYEL's Roe	LYEL's Valuation Ratios	LYEL's Financial Strength Ratios	LYEL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T20:47:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.